Astel­las scores a pair of tri­al wins for menopausal hot flash med, rais­ing the pitch of loom­ing Bay­er stand­off

Astel­las took a fli­er on women’s health when it bought out Oge­da and non­hor­mon­al menopause can­di­date fe­zo­line­tant in ear­ly 2017 and then dou­bled down dur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER